78/100BEdwards Lifesciences stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Edwards Lifesciences is 108.70, 1.2% above the current price of 107.38. Their targets range from 100.00 to 120.00.
Of the 18 firms that rated Edwards Lifesciences in the past 12 months, 15 rate it buy or strong buy, 3 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 100.00 to 120.00, with an average of 108.70.
| Buy | 15 | |
| Hold | 3 | |
| Sell | 0 |
12-month price target
| Highest target | 120.00 |
| Average target | 108.70 |
| Lowest target | 100.00 |
| Current price | 107.38 |
Edwards Lifesciences price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Edwards Lifesciences price target and rating?
How analysts rate Edwards Lifesciences, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
15 of 18 firms rate it buy now, against 13 of 20 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Edwards Lifesciences analyst upgrades, downgrades and price targets
The latest rating change came on 4 November 2026, when Truist Financial upgraded Edwards Lifesciences from Hold to Buy. Its price target is 113.00, from 95.00. The most recent new target came from Truist Financial on 5 November 2026: 118.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 5 Nov 2026 | Truist Financial Richard Newitter | Reiterated · Buy | 113.00 → 118.00 | +4.4% | 101.05 |
| 5 Nov 2026 | Wells Fargo Lawrence Biegelsen | Reiterated · Overweight | 100.00 → 113.00 | +13.0% | 99.37 |
| 5 Nov 2026 | Mizuho Securities Anthony Petrone | — | 95.00 → 120.00 | +26.3% | 99.37 |
| 4 Nov 2026 | Truist Financial Richard Newitter | Upgraded · Hold → Buy | 95.00 → 113.00 | +18.9% | 95.19 |
| 27 Oct 2026 | Deutsche Bank | — | 104.00 | — | 90.56 |
| 28 Jul 2026 | UBS | — | 94.00 → 110.00 | +17.0% | 83.04 |
| 24 Jul 2026 | Piper Sandler | Reiterated · Overweight | 100.00 → 101.00 | +1.0% | 83.82 |
| 24 Jul 2026 | Leerink Partners Mike Kratky | Upgraded · Market Perform → Outperform | 101.00 | — | 83.82 |
| 16 Jul 2026 | Truist Financial Richard Newitter | Reiterated · Hold | 90.00 → 95.00 | +5.6% | 86.79 |
| 13 Jul 2026 | RBC Capital | Reiterated · Outperform | 100.00 → 110.00 | +10.0% | 92.03 |
| 6 Jul 2026 | Evercore ISI | Reiterated · Outperform | 93.00 → 100.00 | +7.5% | 93.12 |
| 30 Jun 2026 | BTIG Marie Thibault | Reiterated · Buy | 100.00 → 110.00 | +10.0% | 91.18 |
| 27 Apr 2026 | Barclays | Reiterated · Overweight | 104.00 → 110.00 | +5.8% | 84.15 |
| 24 Apr 2026 | Truist Financial | Reiterated · Hold | 89.00 → 90.00 | +1.1% | 83.15 |
| 24 Apr 2026 | Evercore ISI Vijay Kumar | Reiterated · Outperform | 94.00 → 93.00 | -1.1% | 83.12 |
| 24 Apr 2026 | BTIG | Reiterated · Buy | 103.00 → 100.00 | -2.9% | 79.72 |
| 24 Apr 2026 | Canaccord Genuity William Plovanic | Reiterated · Hold | 87.00 → 85.00 | -2.3% | 79.72 |
| 13 Apr 2026 | Mizuho Securities | Reiterated · Outperform | 95.00 | — | 77.28 |
| 11 Feb 2026 | Truist Financial Richard Newitter | Reiterated · Hold | 92.00 → 89.00 | -3.3% | 76.85 |
| 11 Feb 2026 | Goldman Sachs David Roman | Reiterated · Buy | 108.00 → 95.00 | -12.0% | 77.05 |
| 11 Feb 2026 | Piper Sandler | Reiterated · Overweight | 98.00 → 100.00 | +2.0% | 77.05 |
| 4 Feb 2026 | UBS Danielle Antalffy | — | 95.00 → 94.00 | -1.1% | 81.63 |
| 20 Jan 2026 | Stifel Nicolaus | Reiterated · Buy | 105.00 → 110.00 | +4.8% | 84.35 |
| 20 Jan 2026 | Piper Sandler | Reiterated · Overweight | 98.00 | — | 84.35 |
| 12 Jan 2026 | UBS Danielle Antalffy | Reiterated · Neutral | 92.00 → 95.00 | +3.3% | 83.58 |
| 12 Jan 2026 | Robert W. Baird | — | 87.00 → 90.00 | +3.4% | 83.69 |
| 12 Jan 2026 | Barclays | Reiterated · Overweight | 103.00 → 104.00 | +1.0% | 85.13 |
| 9 Jan 2026 | Goldman Sachs David Roman | — | 104.00 → 108.00 | +3.8% | 84.58 |
| 9 Jan 2026 | TD Cowen | Upgraded · Hold → Buy | — | — | — |
| 7 Jan 2026 | Stifel Nicolaus Rick Wise | Reiterated · Buy | 100.00 → 105.00 | +5.0% | 85.85 |
| 5 Jan 2026 | Evercore ISI | — | 88.00 → 94.00 | +6.8% | 84.35 |
| 18 Dec 2025 | Wells Fargo | — | 96.00 → 100.00 | +4.2% | 84.84 |
| 18 Dec 2025 | JP Morgan | Upgraded · Neutral → Overweight | — | — | — |
| 17 Dec 2025 | Canaccord Genuity William Plovanic | Reiterated · Hold | 89.00 → 87.00 | -2.2% | 85.32 |
| 16 Dec 2025 | Robert W. Baird David Rescott | — | 88.00 → 87.00 | -1.1% | 83.38 |
| 8 Dec 2025 | Barclays | Reiterated · Overweight | 99.00 → 103.00 | +4.0% | 86.19 |
| 5 Dec 2025 | UBS | Reiterated · Neutral | 90.00 → 92.00 | +2.2% | 86.59 |
| 5 Dec 2025 | RBC Capital Shagun Singh | Reiterated · Outperform | 95.00 → 100.00 | +5.3% | 87.34 |
| 5 Dec 2025 | Robert W. Baird David Rescott | — | 83.00 → 88.00 | +6.0% | 85.78 |
| 5 Dec 2025 | Canaccord Genuity William Plovanic | Reiterated · Hold | 84.00 → 89.00 | +6.0% | 85.78 |
| 5 Dec 2025 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 96.00 | — | 85.78 |
| 5 Dec 2025 | Stifel Nicolaus Rick Wise | Reiterated · Buy | 85.00 → 100.00 | +17.6% | 85.78 |
| 5 Dec 2025 | Truist Financial Richard Newitter | Reiterated · Hold | 87.00 → 92.00 | +5.7% | 85.78 |
| 4 Dec 2025 | BTIG Marie Thibault | — | 103.00 | — | 85.78 |
Edwards Lifesciences EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Edwards Lifesciences's EPS to grow 28.0% a year until 2028. Over the last 5 years it grew 7.1% a year, and over the last 3 years it fell 9.1%.
Analysts expect Edwards Lifesciences's revenue to grow 10.7% a year until 2028, faster than over the last 5 years (6.7% a year) and the last 3 years (4.1%).
Revenue
EPS
Does Edwards Lifesciences beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 5.4% off the result, either way, and their revenue estimate 4.3%, over the last 12 quarters.
- EPS beats
- 73 / 107
- Revenue beats
- 73 / 107
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +4.4%
- Since
- August 2000
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 4 Nov 2026 | 0.74 | 0.80 | +7.5% | 1.68B | 1.72B | +2.1% |
| Q2 FY2026 | 23 Jul 2026 | 0.74 | 0.78 | +5.0% | 1.70B | 1.74B | +2.4% |
| Q1 FY2026 | 23 Apr 2026 | 0.73 | 0.78 | +7.0% | 1.60B | 1.65B | +3.2% |
| Q4 FY2025 | 10 Feb 2026 | 0.62 | 0.58 | -6.1% | 1.55B | 1.57B | +1.5% |
| Q3 FY2025 | 30 Oct 2025 | 0.60 | 0.67 | +12.4% | 1.50B | 1.55B | +3.7% |
| Q2 FY2025 | 24 Jul 2025 | 0.62 | 0.67 | +7.4% | 1.49B | 1.53B | +3.0% |
| Q1 FY2025 | 23 Apr 2025 | 0.60 | 0.64 | +7.4% | 1.40B | 1.41B | +0.9% |
| Q4 FY2024 | 11 Feb 2025 | 0.55 | 0.59 | +7.1% | 1.36B | 1.39B | +2.0% |
| Q3 FY2024 | 24 Oct 2024 | 0.67 | 0.67 | +0.8% | 1.54B | 1.35B | -12.3% |
| Q2 FY2024 | 24 Jul 2024 | 0.69 | 0.70 | +1.4% | 1.65B | 1.39B | -16.2% |
| Q1 FY2024 | 25 Apr 2024 | 0.64 | 0.66 | +3.1% | 1.57B | 1.60B | +1.8% |
| Q4 FY2023 | 6 Feb 2024 | 0.64 | 0.64 | 0.0% | 1.49B | 1.53B | +2.7% |
Edwards Lifesciences stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Edwards Lifesciences's earnings keep growing at the 14.4% a year analysts expect to FY2028, it would earn about 5.03 a share in FY2030. At the P/E it has traded at over the last five years (10.6 to 53.8) that is 53.30 to 270.13 a share, or 174.91 at its average P/E of 34.8. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 3.02 | 31.98 | 104.95 | 162.09 |
| FY2027 | 3.40 | 36.11 | 118.50 | 183.01 |
| FY2028 | 3.84 | 40.70 | 133.55 | 206.26 |
| FY2029 (extrapolated) | 4.39 | 46.57 | 152.84 | 236.04 |
| FY2030 (extrapolated) | 5.03 | 53.30 | 174.91 | 270.13 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 14.4% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (10.6, 34.8, 53.8).
Is Edwards Lifesciences stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Edwards Lifesciences's P/E of 60.7 is near the top of its 5-year range (9.5 to 60.7, median 35.8). It is within 5% of its 5-year high. Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 2.2 on expected growth against 5.1 on its median P/E and past five years' growth. Fair value is not a reliable guide for Edwards Lifesciences: its earnings swing (EPS fell 73.7% in FY2025), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 35.6.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 60.67
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 35.82
- Five-year P/E range
- 9.5 – 60.7
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 35.61
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 4.20
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +1.2%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 235.690 | 464.49205Price 235.69627 | +97.1% | |
| 28.860 | 56.2634Price 28.8696 | +94.9% | |
| 199.110 | 384.58163Price 199.112,644 | +93.1% | |
| 123.990 | 237.24178Price 123.99297 | +91.3% | |
| 157.820 | 297.58169Price 157.82471 | +88.6% | |
| 162.670 | 305.52160Price 162.67396 | +87.8% | |
| 216.610 | 405.38304Price 216.61507 | +87.1% |
Furthest below the fair value on each stock's page, updated every day.